Here we found that T-cells bearing second-generation CARs, which receive in vivo restimulation via a vaccine activating the CAR in lymph nodes, are capable of promoting robust host CD4+ and CD8+ T-cell responses against non-CAR-related tumor antigens. This evidence concerns the gene CD8A and neoplasm.